Article Versions Notes

Staropoli N, Geuna E, Rinaldi G, Bisagni G, Scotti V, Faggioni G, Vannini L, Arcara C, Moretti G, Gunnellini M, et al. Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program. Current Oncology. 2022; 29(9):6635-6641. https://doi.org/10.3390/curroncol29090521

Staropoli, Nicoletta, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini, and et al. 2022. "Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program" Current Oncology 29, no. 9: 6635-6641. https://doi.org/10.3390/curroncol29090521

Staropoli, N., Geuna, E., Rinaldi, G., Bisagni, G., Scotti, V., Faggioni, G., Vannini, L., Arcara, C., Moretti, G., Gunnellini, M., Coltelli, L., Verderame, F., Livi, L., Sanna, G., Grasso, D., Abbinante, G., & Ragni, F. (2022). Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program. Current Oncology, 29(9), 6635-6641. https://doi.org/10.3390/curroncol29090521